1. People's Republic of China Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Anhui Fengyuan Pharmaceutical Co., Ltd.

Anhui Fengyuan Pharmaceutical Co., Ltd.

000153.SZ
Anhui Fengyuan Pharmaceutical Co., Ltd.CN flagShenzhen Stock Exchange
5.26
CNY
-0.03
- -
2.44BMarket Cap
Anhui Fengyuan Pharmaceutical Co., Ltd.
000153.SZ
(Shenzhen Stock Exchange)

Recent

price

5.26

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
2.95
4.18
4.55
3.65
3.89
3.59
4.65
5.89
6.79
7.4
7.6
8.36
9.02
9.2
9.22
8.3
8.61
Revenue per Share
0.11
0.03
0.05
0.07
0.09
0.08
0.1
0.15
0.14
0.18
0.24
0.28
0.35
0.34
0.35
0.21
0.29
Basic EPS, GAAP
-0.1
-0.04
-0.14
-0.44
-0.38
0.02
0.13
0.01
0.34
-0.18
0.23
0.24
0.81
0.22
-0.04
-0.22
-0.44
Free Cash Flow per Basic Share
0.04
0.04
0.06
0.12
0.07
0.07
0.14
0.08
0.07
0.12
0.09
0.06
0.13
0.14
0.16
0.17
0.15
Dividend per Share
1.21
1.16
1.21
1.17
1.21
1.25
1.28
1.44
1.55
1.67
1.9
2.19
2.47
2.63
3.13
3.24
3.19
Book Value per Share
1.63
1.61
1.63
2.24
2.2
2.32
2.29
2.45
2.51
2.62
2.81
3.52
3.38
3.5
3.75
3.9
3.91
Tangible Book Value per Share
364
364
364
419
437
437
437
438
444
438
437
437
444
465
465
465
465
Basic Weighted Avg Shares
1,074
1,521
1,658
1,530
1,699
1,569
2,034
2,578
3,013
3,238
3,321
3,652
4,004
4,275
4,285
3,858
4,004
Sales/Revenue/Turnover
3.98
1.37
2.24
3.35
3.87
4.1
4.52
5.16
4.61
4.86
4.85
5.52
5.8
5.66
5.76
4.83
4.68
Operating Margin (%)
50
51
52
59
69
64
69
75
75
71
71
115
122
126
128
148
- -
Depreciation Expense
42
11
19
27
41
35
46
65
61
81
104
123
154
159
161
99
137
Net Income, GAAP
23.01
26.02
28.45
33.93
27.09
25.31
31.32
32.41
34.79
32.79
26.08
26.26
25.38
26.8
24.47
24.27
17.16
Effective Tax Rate (%)
3.88
0.72
1.15
1.79
2.41
2.24
2.25
2.53
2.02
2.5
3.12
3.37
3.86
3.73
3.75
2.58
3.42
Profit Margin (%)
68
9
10
266
9
-26
-71
6
-52
-296
-363
-70
-267
-111
-223
-280
-240
Working Capital
40
- -
60
197
68
59
43
- -
- -
105
65
115
190
195
213
300
242
LT Debt
754
764
775
1,120
1,147
1,199
1,153
1,220
1,292
1,327
1,448
1,771
1,755
1,919
2,046
2,126
2,119
Total Equity
3.37
1.54
2.52
2.52
2.95
2.81
3.6
5.13
5.27
5.83
5.8
6.49
6.91
6.77
6.55
4.48
5.15
Return on Invested Capital (%)
7.49
3.13
4.5
4.62
6.13
5.36
5.77
7.68
7.41
8.89
9.38
9.95
10.36
9.67
8.49
5.15
6.9
Return on Capital (%)
9.91
2.55
4.41
5.89
8.05
6.55
8.31
11
9.25
11.42
13.29
13.77
15.05
13.75
12.02
6.72
9.48
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
ST Debt
771
739
774
LT Borrowings
196
273
226
LT Finance Leases
17
15
16
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
465
465
465
Market Capitalization
2,850
2,859
2,868

Working Capital

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
Total Current Assets
1,965
2,022
1,986
Cash, Cash Equivalents & STI
251
228
188
Accounts Receivable, Net
935
1,016
1,085
Inventories
593
598
558
Total Current Liabilities
2,188
2,168
2,225
Payables & Accruals
- -
- -
- -
ST Debt
771
739
774
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
6.1%
8.25%
3.91%
Free Cash Flow
377.13%
105.14%
469.76%
Net Income, GAAP
13.71%
2.01%
-38.19%
Sales/Revenue/Turnover
9.99%
3.33%
-9.95%
Total Cash Common Dividend
20.31%
24.75%
12.46%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1,121
1,187
954
1,023
4,285
2025
941
1,086
733
- -
3,858
2026
836
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.1
- -
- -
- -
0.35
2025
0.08
- -
- -
- -
0.21
2026
0.08
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.01
- -
- -
- -
0.16
2025
0.02
- -
- -
- -
0.17
2026
0.02
- -
- -
- -
- -
Similar Companies
Hybio Pharmaceutical Co., Ltd. (300199.SZ)
Pharmaxis Ltd (PXS.AX)
Live Verdure Ltd (LV1.AX)
Ildong Holdings Co., Ltd. (000230.KS)
Yooma Wellness Inc. (YOOM.CN)
Medical Developments International Limited (MDDVF)
Business
Anhui Fengyuan Pharmaceutical Co., Ltd. (000153.SZ) researches, develops, produces, and sells a broad range of pharmaceutical products primarily in China, with exports to Africa, Southeast Asia, Central Asia, Europe, and other international markets. The company offers biopharmaceuticals, chemical pharmaceuticals, Chinese patent medicines, Chinese herbal decoction pieces, and active pharmaceutical ingredients (APIs), spanning categories such as gynecology, respiratory system, hormonal, antipyretic analgesic, mental health, antiviral, antibiotic, oral anesthetic, masks, urinary, water electrolyte balance, digestive system, cardiovascular, Yinpian, and nutrition and metabolism; key products include peritoneal dialysis solutions, electrolyte series, fructose series, fatty milk emulsions, amino acid series, ambroxol hydrochloride injections, isosorbide mononitrate injections, levofloxacin lactate injections, ibutilide fumarate injections, cilnidipine tablets, dexamethasone phosphate injections, oxytocin injections, and diclofenac sodium patches. Founded in 1997 and headquartered at No. 16 Dalian Road, Baohe Industrial Park, Hefei, Anhui Province, China, it operates as a high-tech enterprise and the first listed pharmaceutical company in Anhui Province, integrating R&D, manufacturing, and commercial distribution across multiple dosage forms and over 300 varieties. In recent developments, the company reported operating revenue growth in its Q3 2025 financials, with a strategic focus for 2025 on expanding core high-margin varieties, enhancing refined management for cost efficiency, accelerating new drug development, and increasing classic traditional Chinese medicine formulas to enrich its pipeline amid low current TCM revenue contribution of less than 1%. It continues to prioritize biopharmaceuticals, chemical drugs, and traditional Chinese medicines while pursuing operational efficiencies and product diversification.